CCND1 and neoplasm: Our findings of CCND1 and/or CDK4 allow us the suggestion that the selective CDK4/6 inhibitor Palbociclib (IBRANCE®, Pfizer Inc.)may be a promising treatment option in unresectable or metastasized tumor stages.